Metformin Shows Consistent Benefits Across Renal Functions in Type 2 Diabetes Patients, finds observational study

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-03-06 23:30 GMT | Update On 2024-03-08 04:24 GMT

In a recent observational study spanning three tertiary hospitals, researchers have uncovered compelling evidence supporting the widespread efficacy of metformin, the primary treatment for type 2 diabetes mellitus (T2DM). The study, which focused on patients with preserved renal function, aimed to bridge existing gaps in understanding the impact of metformin on various renal conditions. The study concluded that Metformin use in T2DM patients across various renal functions consistently correlates with a decreased risk of overt diabetic nephropathy (DN), major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE).

The study results were published in the journal Scientific Reports.

Also Read: Evergreen Talk Series: Combination of Linagliptin and Dapagliflozin in T2DM with multiple episodes of hypoglycemia

Metformin, renowned as the cornerstone treatment for type 2 diabetes mellitus (T2DM), has long been hailed for its efficacy in enhancing clinical outcomes among individuals with maintained renal function. However, a notable knowledge gap persists regarding the extent of metformin's effectiveness across diverse renal functions. Hence, researchers conducted a retrospective, multicenter study by utilizing data from three tertiary hospitals' databases, drawing on the medical records of patients with T2DM.The metformin cohort comprised individuals who had been prescribed metformin during run-in periods and received at least one additional prescription, while the control cohort included those prescribed oral hypoglycemic agents other than metformin, with no subsequent metformin prescriptions during the observation period.For patients without diabetic nephropathy (DN), the study investigated outcomes such as events of DN, major adverse cardiovascular events (MACE), and major adverse kidney events (MAKE). Following meticulous 1:1 propensity matching, 1994 individuals were selected for both the metformin and control cohorts among T2DM patients without baseline DN.

Findings:

The study's findings revealed intriguing insights into metformin's impact on clinical outcomes.
While the incidence rate ratio (IRR) for DN events showed no significant difference between the cohorts (IRR 1.06, 95% CI 0.96–1.17), metformin emerged as a potent protective factor against major adverse cardiovascular events (MACE) with an IRR of 0.76 (0.64–0.92).
Moreover, metformin showcased remarkable efficacy in reducing major adverse kidney events (MAKE) with an IRR of 0.45 (0.33–0.62).
Delving deeper into the data, the study explored outcomes based on renal function subgroups, including CKD 3A, 3B, and 4.In CKD 3A, metformin demonstrated significant benefits with an IRR of 0.70 (0.57–0.87) for MACE and 0.39 (0.35–0.43) for MAKE.
Similarly, in CKD 3B, the IRRs were 0.83 (0.74–0.93) for MACE and 0.44 (0.40–0.48) for MAKE.
In CKD 4, metformin continued to exhibit positive effects, with IRRs of 0.71 (0.60–0.85) for MACE and 0.45 (0.39–0.51) for MAKE.

Also Read: Add on Metformin can offset weight gain due to medicines for bipolar disorder

The study's lead researcher emphasized that the findings suggest metformin's consistent correlation with a reduced risk of overt DN, MACE, and MAKE across various renal functions in T2DM patients. However, it's crucial to note that this study is observational, and further research, including randomized controlled trials, is essential to validate these promising results. As the medical community eagerly awaits further research, these findings shed light on the potential multifaceted benefits of metformin, offering hope for improved outcomes in T2DM patients, particularly those with varying levels of renal function.

Further reading: Impact of metformin on cardiovascular and kidney outcome based on kidney function status in type 2 diabetic patients: a multicentric, retrospective cohort study. https://doi.org/10.1038/s41598-024-52078-4

Article Source : Scientific Reports

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr.Niharika Harsha B

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Metformin Shows Consistent Benefits Across Renal Functions in Type 2 Diabetes Patients, finds observational study

Similar News

Healthy Diet Patterns Lower Type 2 Diabetes Risk Across Ethnicities: Meta-Analysis of 800,000+ Individuals shows

Low FT4 Levels Linked to Higher Gestational Diabetes Risk: Study

Hypothyroidism May Lower Breast Cancer Risk, Especially After Menopause: Study

Age at woman’s first period can offer clues about long-term health risks: Study

A new diabetes subtype identified in Sub-Saharan Africa and Black Americans, study finds

Indian Study Shows Type 2 Diabetes Remission May Be Possible without Surgery or Extreme Diets

Can This Common Diabetes Drug Prevent Stroke? Emerging Data Suggests Strong Link

'Inflammatory' diet during pregnancy may raise child's diabetes type 1 risk: Research